Efficacy of prebiotic, probiotic and synbiotic administration in improving growth in children aged 0-59 months living in low- and middle-income countries: a systematic review and meta-analysis.

IF 2 3区 医学 Q2 PEDIATRICS
Marietou Khouma, Mamadou Diallo, Doudou Sow, Aicha Djigal, Ndeye Sokhna Diop, Stephen Allen, Babacar Faye
{"title":"Efficacy of prebiotic, probiotic and synbiotic administration in improving growth in children aged 0-59 months living in low- and middle-income countries: a systematic review and meta-analysis.","authors":"Marietou Khouma, Mamadou Diallo, Doudou Sow, Aicha Djigal, Ndeye Sokhna Diop, Stephen Allen, Babacar Faye","doi":"10.1186/s12887-025-05503-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Poor growth is one of the major obstacles to human development, affecting millions of children under the age of 5 years, particularly those living in low- and middle-income countries (LMICs). The objective of this review was to evaluate the efficacy of administering pre-, pro- or synbiotics on the growth of children aged 0-59 months living in LMICs.</p><p><strong>Methods: </strong>Google scholar, Pubmed, clinical trial.org and Science Direct databases were searched in April 2023 for randomised controlled trials of pre-, pro- or synbiotics that evaluated growth in under fives in LMICs. The primary outcome were weight and height gain. Secondary outcomes were head circumference, body mass index gain and Z score. Random-effects meta-analysis was used to calculate mean differences for continuous outcomes. Grading of Recommendations Assessment, Development and Evaluation criteria was used to assess certainty of the evidence.</p><p><strong>Results: </strong>Eight trials involving 1375 children under 5 years of age were identified. Meta-analysis of 6 RCTs (n = 991 children) revealed a significant difference in favor of the experimental group (n = 579) compared the control group (n = 412) for weight gain: (MD = 0.33 kg, 95% CI 0.11 to 0.55); low-certainty evidence. Sub-group analysis revealed that pre-, pro, or synbiotics may be more effective in malnourished that healthy children (p = 0.003). Meta-analysis of height gain for 4 RCTs (n = 845) found that there was no significant difference between the experimental group (n = 496) and the control group (n = 349) (MD = 0.31 cm; 95% CI -0.36 to 0.98); low-certainty evidence. In sub-group analysis, prebiotics had a greater impact on height gain than synbiotics (p = 0.03). In the only study reporting an increase in head circumference (n = 32 children), this was not improved by the administration of synbiotics. However, administration of synbiotics to undernourished children significantly improved BMI gain.</p><p><strong>Conclusion: </strong>The evidence for the administration of pre-, pro- or synbiotics on the growth of children in LMICs is weak. Administration of pre-, pro- or synbiotics may improve weight gain in both healthy and malnourished children. Prebiotics and synbiotics had a significant effect on weight gain. Further research is needed due to the small number of studies, short duration of administration and small sample size.</p>","PeriodicalId":9144,"journal":{"name":"BMC Pediatrics","volume":"25 1","pages":"149"},"PeriodicalIF":2.0000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866818/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12887-025-05503-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Poor growth is one of the major obstacles to human development, affecting millions of children under the age of 5 years, particularly those living in low- and middle-income countries (LMICs). The objective of this review was to evaluate the efficacy of administering pre-, pro- or synbiotics on the growth of children aged 0-59 months living in LMICs.

Methods: Google scholar, Pubmed, clinical trial.org and Science Direct databases were searched in April 2023 for randomised controlled trials of pre-, pro- or synbiotics that evaluated growth in under fives in LMICs. The primary outcome were weight and height gain. Secondary outcomes were head circumference, body mass index gain and Z score. Random-effects meta-analysis was used to calculate mean differences for continuous outcomes. Grading of Recommendations Assessment, Development and Evaluation criteria was used to assess certainty of the evidence.

Results: Eight trials involving 1375 children under 5 years of age were identified. Meta-analysis of 6 RCTs (n = 991 children) revealed a significant difference in favor of the experimental group (n = 579) compared the control group (n = 412) for weight gain: (MD = 0.33 kg, 95% CI 0.11 to 0.55); low-certainty evidence. Sub-group analysis revealed that pre-, pro, or synbiotics may be more effective in malnourished that healthy children (p = 0.003). Meta-analysis of height gain for 4 RCTs (n = 845) found that there was no significant difference between the experimental group (n = 496) and the control group (n = 349) (MD = 0.31 cm; 95% CI -0.36 to 0.98); low-certainty evidence. In sub-group analysis, prebiotics had a greater impact on height gain than synbiotics (p = 0.03). In the only study reporting an increase in head circumference (n = 32 children), this was not improved by the administration of synbiotics. However, administration of synbiotics to undernourished children significantly improved BMI gain.

Conclusion: The evidence for the administration of pre-, pro- or synbiotics on the growth of children in LMICs is weak. Administration of pre-, pro- or synbiotics may improve weight gain in both healthy and malnourished children. Prebiotics and synbiotics had a significant effect on weight gain. Further research is needed due to the small number of studies, short duration of administration and small sample size.

背景:发育不良是人类发展的主要障碍之一,影响着数百万 5 岁以下的儿童,尤其是生活在中低收入国家(LMICs)的儿童。本综述旨在评估使用益生菌前体、益生菌原或合成益生菌对生活在低收入和中等收入国家的 0-59 个月大儿童生长发育的影响:2023 年 4 月,在 Google scholar、Pubmed、clinical trial.org 和 Science Direct 数据库中搜索了对低收入国家五岁以下儿童生长进行评估的益生菌前体、益生菌或合成益生菌随机对照试验。主要结果是体重和身高的增长。次要结果为头围、体重指数增长和 Z 评分。随机效应荟萃分析用于计算连续结果的平均差异。采用建议评估、发展和评价分级标准来评估证据的确定性:结果:共确定了 8 项试验,涉及 1375 名 5 岁以下儿童。对 6 项研究性试验(n = 991 名儿童)进行的元分析表明,实验组(n = 579 名)与对照组(n = 412 名)相比,在体重增加方面存在显著差异:(MD = 0.33 千克,95% CI 0.11 至 0.55);证据确定性较低。分组分析表明,预益生菌、促益生菌或合成益生菌对营养不良儿童可能比对健康儿童更有效(P = 0.003)。对 4 项 RCT(n = 845)进行的身高增长元分析发现,实验组(n = 496)与对照组(n = 349)之间没有显著差异(MD = 0.31 厘米;95% CI -0.36 至 0.98);低确定性证据。在亚组分析中,益生元对身高增长的影响大于合成益生元(p = 0.03)。在唯一一项报告头围增加的研究中(n = 32 名儿童),服用益生菌并未改善头围的增加。然而,给营养不良的儿童服用益生菌可显著改善体重指数的增长:在低收入和中等收入国家,使用益生菌前体、益生菌原或益生菌能促进儿童生长的证据不足。服用益生菌、益生元或合成益生菌可提高健康儿童和营养不良儿童的体重增长。益生元和合成益生菌对体重增加有显著影响。由于研究数量少、用药时间短和样本量小,还需要进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Pediatrics
BMC Pediatrics PEDIATRICS-
CiteScore
3.70
自引率
4.20%
发文量
683
审稿时长
3-8 weeks
期刊介绍: BMC Pediatrics is an open access journal publishing peer-reviewed research articles in all aspects of health care in neonates, children and adolescents, as well as related molecular genetics, pathophysiology, and epidemiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信